{
  "nctId": "NCT02392611",
  "briefTitle": "Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer",
  "officialTitle": "A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) as a Monotherapy in Subjects With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Subjects With Estrogen Receptor Positive Breast Cancer",
  "protocolDocument": {
    "nctId": "NCT02392611",
    "filename": "Prot_000.pdf",
    "label": "Study Protocol",
    "date": "2016-06-20",
    "uploadDate": "2020-10-13T16:03",
    "size": 7451240,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT02392611/document/Prot_000.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [
    "PHASE1"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "NON_RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 33,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2015-03-16",
    "completionDate": "2017-10-11",
    "primaryCompletionDate": "2017-10-11",
    "firstSubmitDate": "2015-03-13",
    "firstPostDate": "2015-03-19"
  },
  "eligibilityCriteria": {
    "criteria": "Key Inclusion Criteria:\n\n* Group 1: Histologically or cytologically confirmed advanced malignant solid tumor or lymphoma (any subtype) that is refractory to or intolerant of standard therapy or for which no standard therapy is available\n* Group 2: Post-menopausal women with advanced stage estrogen receptor positive breast cancer who are candidates for exemestane or fulvestrant\n* Group 3: Individuals with lymphoma are limited to diffuse large B-cell lymphoma and peripheral T-cell lymphoma that are refractory to or intolerant of standard therapy or for which no standard therapy is available\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 1\n* Adequate organ function defined as follows:\n\n  * Hematologic: Platelets ≥ 100 x 10\\^9/L; Hemoglobin ≥ 9.0 g/ dL; Absolute neutrophil count (ANC) ≥ 1.5 x 10\\^9/L (without platelet transfusion or any growth factors within previous 7 days of the hematologic laboratory values obtained at screening visit). Participants in the Group 3 lymphoma expansion may be enrolled with an ANC of ≥ 1.0 x 10\\^9 /L; Platelets ≥ 75 x 10\\^9 /L.\n  * Hepatic: Aspartate transaminase (AST) / Alanine transaminase (ALT) ≤ 2.5 x upper limit of normal (ULN) (if liver metastases are present, ≤ 5 x ULN); Total or conjugated bilirubin ≤ 1.5 x ULN\n  * Renal: Serum creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥ 60 ml/min as calculated by the cockcroft-gault method\n* Coagulation: International Normalized Ratio (INR) ≤ 1.2\n\nKey Exclusion Criteria:\n\n* Known brain metastasis or leptomeningeal disease\n* Myocardial infarction, symptomatic congestive heart failure (New York Heart Association Classification \\> Class II), unstable angina, or serious uncontrolled cardiac arrhythmia within the last 6 months of study Day 1\n* Major surgery, defined as any surgical procedure that involves general anesthesia and a significant incision (ie, larger than what is required for placement of central venous access, percutaneous feeding tube, or biopsy) within 28 days of first dose of study drug\n* History of long QT syndrome or whose corrected QT interval (QTc) measured (Fridericia method) at screening is prolonged (\\> 450 ms for males and \\> 470 ms for females). Individuals who screen-fail due to this criterion are not eligible to be re-screened\n* Clinically significant bleeding within 28 days of study Day 1\n* Known human immunodeficiency virus (HIV) infection\n* Hepatitis B surface antigen positive\n* Hepatitis C virus (HCV) antibody positive\n* No active anticoagulation within 7 days of study Day 1; including acetylsalicylic acid, low molecular weight heparin, or warfarin.\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Number of Participants Experiencing Dose Limiting Toxicities (DLTs)",
        "description": "A DLT was a toxicity, considered possibly related to alobresib, and which occurred during DLT assessment window (Day 1 through Cycle 1 Day 28) in each cohort: Grade ≥ 4 neutropenia (absolute neutrophil count \\[ANC\\] \\< 500/mm\\^3); Grade ≥3 neutropenia (ANC\\< 1000/mm\\^3) with fever (a single temperature of \\> 38.3°C or a sustained temperature of ≥ 38°C for more than 1 hour \\[hr\\]); Grade ≥ 3 thrombocytopenia; Grade ≥ 2 bleeding; Grade ≥ 3 non hematologic toxicity, except Grade 3 nausea or emesis with maximum duration of 48 hrs on adequate medical therapy and Grade 3 diarrhea which persists for \\< 72 hrs in absence of maximal medical therapy; Grade ≥ 2 non hematologic treatment-emergent adverse event (TEAE) of potential clinical significance; treatment interruption ≥ 7 days due to unresolved toxicity; and any Grade 3 or 4 elevation in aspartate aminotransferase (AST) or alanine aminotransferase (ALT) associated with a Grade 2 elevation in bilirubin that is at least possibly related to alobresib.",
        "timeFrame": "Baseline (Day 1) up to 28 days"
      }
    ],
    "secondary": [
      {
        "measure": "Pharmacokinetic (PK) Parameter: Cmax of Alobresib",
        "description": "Cmax is defined as the maximum concentration of the drug.",
        "timeFrame": "Cycle 1: Predose (0 hr), 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hrs postdose on Days 1 and 8 (1 Cycle = 28 days)"
      },
      {
        "measure": "PK Parameter: Ctau of Alobresib",
        "description": "Ctau is defined as the observed drug concentration at the end of the dosing interval.",
        "timeFrame": "Cycle 1: Predose (0 hr), 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hrs postdose on Day 8 (1 Cycle = 28 days)"
      },
      {
        "measure": "PK Parameter: AUC0-24 of Alobresib",
        "description": "AUC0-24 is defined as the concentration of drug over time from time zero to time 24 hrs.",
        "timeFrame": "Cycle 1: Predose (0 hr), 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hrs postdose on Days 1 and 8 (1 Cycle = 28 days)"
      },
      {
        "measure": "PK Parameter: AUCtau of Alobresib",
        "description": "AUCtau is defined as the concentration of drug over time (the area under the concentration verses time curve over the dosing interval).",
        "timeFrame": "Cycle 1: Predose (0 hr), 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hrs postdose on Day 8 (1 Cycle = 28 days)"
      },
      {
        "measure": "PK Parameter: Tmax of Alobresib",
        "description": "Tmax is defined as the time (observed time point) of Cmax.",
        "timeFrame": "Cycle 1: Predose (0 hr), 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hrs postdose on Days 1 and 8 (1 Cycle = 28 days)"
      },
      {
        "measure": "PK Parameter: t1/2 of Alobresib",
        "description": "t1/2 is defined as the estimate of the terminal elimination half-life of the drug. Due to short sampling period of the terminal elimination phase in these cohorts t1/2 values should be interpreted with caution.",
        "timeFrame": "Cycle 1: Predose (0 hr), 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hrs postdose on Days 1 and 8 (1 Cycle = 28 days)"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 6,
      "otherCount": 0,
      "totalCount": 7
    },
    "studyDesign": {
      "phases": [
        "PHASE1"
      ],
      "isRandomized": false,
      "isMasked": false,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 44,
    "complexityCategory": "Moderate"
  },
  "collectionDate": "2025-09-22T02:29:05.389Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}